標(biāo)題: Titlebook: Bile Acids and Their Receptors; Stefano Fiorucci,Eleonora Distrutti Book 2019 Springer Nature Switzerland AG 2019 Bile acids.Nuclear recep [打印本頁] 作者: 加冕 時(shí)間: 2025-3-21 18:20
書目名稱Bile Acids and Their Receptors影響因子(影響力)
書目名稱Bile Acids and Their Receptors影響因子(影響力)學(xué)科排名
書目名稱Bile Acids and Their Receptors網(wǎng)絡(luò)公開度
書目名稱Bile Acids and Their Receptors網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Bile Acids and Their Receptors被引頻次
書目名稱Bile Acids and Their Receptors被引頻次學(xué)科排名
書目名稱Bile Acids and Their Receptors年度引用
書目名稱Bile Acids and Their Receptors年度引用學(xué)科排名
書目名稱Bile Acids and Their Receptors讀者反饋
書目名稱Bile Acids and Their Receptors讀者反饋學(xué)科排名
作者: LEER 時(shí)間: 2025-3-21 21:00 作者: hair-bulb 時(shí)間: 2025-3-22 02:32
Structural Insight into the Binding Mode of FXR and GPBAR1 Modulators,resenting promising pharmacological targets. We pay particular attention to the chemical and structural features of the ligand-receptor interaction, providing guidelines to achieve ligands endowed with selective or dual activity towards the receptor and paving the way to future drug design studies.作者: conspicuous 時(shí)間: 2025-3-22 06:10 作者: hematuria 時(shí)間: 2025-3-22 11:20 作者: Classify 時(shí)間: 2025-3-22 14:38
,Pflege der Isolier?le im Betrieb,lectively target GPBAR1 or FXR..In this review, we summarize the most recent acquisition on natural, semisynthetic, and synthetic steroidal and nonsteroidal ligands, able to interact with FXR and GPBAR1.作者: 留戀 時(shí)間: 2025-3-22 19:58
https://doi.org/10.1007/978-3-663-07267-6d their activated receptors in mediating the beneficial metabolic effects of bariatric surgery. We also discuss the potential to target bile acid-activated receptors in order to treat obesity and other metabolic diseases.作者: 冷峻 時(shí)間: 2025-3-22 23:07
The Enterokine Fibroblast Growth Factor 15/19 in Bile Acid Metabolism,he liver. However, native FGF19 seems to retain peculiar hepatic pro-tumorigenic actions. Recently engineered FGF19 analogues have been recently synthetized, with fully retained BA regulatory activity but without intrinsic pro-tumoral action, thus opening bona fide novel pharmacological strategy for the treatment of gut-liver axis diseases.作者: Intend 時(shí)間: 2025-3-23 04:34
Chemistry and Pharmacology of GPBAR1 and FXR Selective Agonists, Dual Agonists, and Antagonists,lectively target GPBAR1 or FXR..In this review, we summarize the most recent acquisition on natural, semisynthetic, and synthetic steroidal and nonsteroidal ligands, able to interact with FXR and GPBAR1.作者: Gnrh670 時(shí)間: 2025-3-23 08:08 作者: 大氣層 時(shí)間: 2025-3-23 10:34
Book 2019ajor pharmacological target.?It?covers?all?major areas of?research?in this field, from genetics, chemistry, in silico modeling,?molecular biology to clinical applications,?offering a cross-country view?of?the functional role of bile acids as?signaling molecules, virtually acting on?all major areas o作者: 北極人 時(shí)間: 2025-3-23 15:00 作者: 臆斷 時(shí)間: 2025-3-23 19:55
UDCA, NorUDCA, and TUDCA in Liver Diseases: A Review of Their Mechanisms of Action and Clinical Approphilic BA (i.e., ursodeoxycholic acid, tauroursodeoxycholic, and, more recently, norursodeoxycholic acid), have been revamped. In the present review, we summarize current experimental and clinical data regarding these BAs and its role in the treatment of certain liver diseases.作者: 轉(zhuǎn)折點(diǎn) 時(shí)間: 2025-3-24 00:42
The Pharmacology of Bile Acids and Their Receptors,the liver from cholesterol and have been used for almost half a century for treating liver and biliary disorders. Since the early 1970s of the last century, chenodeoxycholic acid (CDCA), a primary bile acid, and ursodeoxycholic acid (UDCA), a secondary bile acid and the 7βepimer of CDCA, have been s作者: 不能約 時(shí)間: 2025-3-24 06:05 作者: Redundant 時(shí)間: 2025-3-24 08:15 作者: 國家明智 時(shí)間: 2025-3-24 13:48
The Enterokine Fibroblast Growth Factor 15/19 in Bile Acid Metabolism,dial hormone regulating glucose homeostasis, glycogen and protein synthesis, and primary bile acid (BA) metabolism. In the ileum, BA-dependent farnesoid X receptor (FXR) activation induces the production of FGF19, which reaches the liver through the portal system where it represses the expression of作者: MOAT 時(shí)間: 2025-3-24 15:04 作者: 錯(cuò)事 時(shí)間: 2025-3-24 19:33
Structural Insight into the Binding Mode of FXR and GPBAR1 Modulators,and the G-protein bile acid receptor 1 (GPBAR1). These two receptors play a key role in many diseases related to lipid and glucose disorders, thus representing promising pharmacological targets. We pay particular attention to the chemical and structural features of the ligand-receptor interaction, p作者: 繁殖 時(shí)間: 2025-3-25 02:36
Chemistry and Pharmacology of GPBAR1 and FXR Selective Agonists, Dual Agonists, and Antagonists,rgets for the treatment of several diseases, ranging from liver cholestatic disorders to metabolic syndrome, inflammatory states, nonalcoholic steatohepatitis (NASH), and diabetes..Consequently, the development of dual FXR/GPBAR1 agonists, as well as selective targeting of one of these receptors, is作者: CESS 時(shí)間: 2025-3-25 07:22 作者: 叢林 時(shí)間: 2025-3-25 09:35
Potential of Intestine-Selective FXR Modulation for Treatment of Metabolic Disease,s own ligands, i.e., bile acids, but also regulates glucose and lipid metabolism as well as the immune system. These findings have led to substantial interest for FXR as a therapeutic target and to the recent approval of an FXR agonist for treating primary biliary cholangitis as well as ongoing clin作者: 詞匯 時(shí)間: 2025-3-25 13:00 作者: 違法事實(shí) 時(shí)間: 2025-3-25 17:50
Chenodeoxycholic Acid: An Update on Its Therapeutic Applications,CA is conjugated with glycine or taurine to form two bile salts, Glyco-CDCA and Tauro-CDCA, before being released into the bile ducts. In the intestine, CDCA is further metabolized to generate a 7β epimer, i.e., the ursodeoxycholic acid (UDCA), or dehydroxylate to generate lithocolic acid (LCA). In 作者: PLUMP 時(shí)間: 2025-3-25 22:41
Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders,xy-5-cholan-24-oic acid), a relatively hydrophobic primary bile acid synthesized in the liver from cholesterol. OCA, also known as 6-ethyl-CDCA or INT-747, was originally described by investigators at the Perugia University in 2002 as a selective ligand for the bile acid sensor, farnesoid-X-receptor作者: forthy 時(shí)間: 2025-3-26 01:31 作者: 改變 時(shí)間: 2025-3-26 07:12
Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steen hepatocellular carcinoma (HCC). The prevalence of NASH is rising and has become a large burden to the medical system worldwide. Unfortunately, despite its high prevalence and severe health consequences, there is currently no therapeutic agent approved to treat NASH. Therefore, the development of 作者: 痛得哭了 時(shí)間: 2025-3-26 11:52
Targeting Bile Acid-Activated Receptors in Bariatric Surgery,s to achieve a significant and sustainable weight loss. Bariatric surgery also concomitantly improves type 2 diabetes and other metabolic diseases such as nonalcoholic steatohepatitis, cardiovascular diseases, and hyperlipidemia. However, despite the recent exciting progress in the understanding how作者: 朝圣者 時(shí)間: 2025-3-26 16:30 作者: BAN 時(shí)間: 2025-3-26 17:34
E. Dupin,C. Ziller,N. M. Le Douarines, while TGR5 is predominately found in non-parenchymal cells. In contrast to S1PR2, which is mainly activated by conjugated bile acids (BAs), all BAs serve as ligands for TGR5 irrespective of their conjugation state and substitution pattern..Mice with targeted deletion of either S1PR2 or TGR5 are 作者: insincerity 時(shí)間: 2025-3-26 20:59
,Der elektrische Durchschlag in Isolier?len,n, and development. Upon activation by their ligands, NRs bind to their specific DNA elements, exerting their biological functions by regulating their target gene expression. Bile acids are detergent-like molecules that are synthesized in the liver. They not only function as a facilitator for the di作者: MERIT 時(shí)間: 2025-3-27 01:41
,Der elektrische Durchschlag in Isolier?len,dial hormone regulating glucose homeostasis, glycogen and protein synthesis, and primary bile acid (BA) metabolism. In the ileum, BA-dependent farnesoid X receptor (FXR) activation induces the production of FGF19, which reaches the liver through the portal system where it represses the expression of作者: 向外供接觸 時(shí)間: 2025-3-27 08:20
,über Elektrizit?tsleitung in Isolier?len,lbladder. After a meal ingestion, BAs are reversed into the duodenum to facilitate the lipid absorption. At the intestinal level, the 95% of BAs are reabsorbed and redirected into enterohepatic circulation; indeed only a small amount of them are then subjected to chemical modifications by the intest作者: chondromalacia 時(shí)間: 2025-3-27 10:49 作者: Debate 時(shí)間: 2025-3-27 17:18 作者: 無辜 時(shí)間: 2025-3-27 19:11
https://doi.org/10.1007/978-3-642-50705-2lerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH). NASH, in particular, is one of the last uncharted white territories in the pharma landscape, and there is a huge medical need and a large potential pharmaceutical market for a NASH pharmacotherapy. Clinical efficacy superior to mos作者: 斜坡 時(shí)間: 2025-3-27 23:14 作者: motivate 時(shí)間: 2025-3-28 05:45
Niels Lange,Thomas O. Hüglin,Thomas J?gervances in the understanding of BA physiology, and new insights have emerged regarding the role of BAs in determining cell damage and death in several liver diseases. This new knowledge has helped to better delineate the pathophysiology of cholestasis and the adaptive responses of hepatocytes to chol作者: 起草 時(shí)間: 2025-3-28 09:55 作者: 前兆 時(shí)間: 2025-3-28 14:30 作者: PIZZA 時(shí)間: 2025-3-28 15:49
https://doi.org/10.1007/978-3-663-07266-9nd intestinal target genes, small heterodimer partner (SHP, NR0B2) and fibroblast growth factor 15/19 (Fgf15 in mice, FGF19 in humans), transcriptionally regulate BA synthesis, detoxification, secretion, and absorption in the enterohepatic circulation. Furthermore, FXR modulates a large variety of p作者: Evocative 時(shí)間: 2025-3-28 19:38 作者: AER 時(shí)間: 2025-3-29 01:40
https://doi.org/10.1007/978-3-663-07267-6s to achieve a significant and sustainable weight loss. Bariatric surgery also concomitantly improves type 2 diabetes and other metabolic diseases such as nonalcoholic steatohepatitis, cardiovascular diseases, and hyperlipidemia. However, despite the recent exciting progress in the understanding how作者: embolus 時(shí)間: 2025-3-29 03:24 作者: archenemy 時(shí)間: 2025-3-29 09:02 作者: 種屬關(guān)系 時(shí)間: 2025-3-29 15:26 作者: addition 時(shí)間: 2025-3-29 16:32 作者: 傳染 時(shí)間: 2025-3-29 21:34 作者: OPINE 時(shí)間: 2025-3-30 00:05
0171-2004 common human?alignments ?including? liver, intestinal and metabolic disorders, such as steatosis (NAFLD) and steato-hepatitis (NASH), diabetes, obesity and atherosclerosis.?978-3-030-22007-5978-3-030-22005-1Series ISSN 0171-2004 Series E-ISSN 1865-0325 作者: incubus 時(shí)間: 2025-3-30 07:55 作者: amenity 時(shí)間: 2025-3-30 09:42 作者: 擁擠前 時(shí)間: 2025-3-30 16:25 作者: perpetual 時(shí)間: 2025-3-30 16:45 作者: 舊石器 時(shí)間: 2025-3-30 21:51 作者: considerable 時(shí)間: 2025-3-31 04:47
